Resources

The AMA has collected more than 400 educational and other resources to provide evidence-based recommendations for physicians and policymakers.

Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder

Putting Evidence Into Practice: Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder. Elizabeth Salisbury-Afshar, MD, MPH, Heartland Health Outreach, Chicago, Illinois. Am Fam Physician. 2015 Feb 1;91(3):165-166.

American Society of Anesthesiologists’ resources on pain management and anesthesia

Learn more about anesthesia, pain management and the medical experts committed to patient safety and high-quality care.

Enhanced Attestation of Mental Health and Substance Use Disorder Parity

Use of this form by state regulators--and health insurers--can help ensure meaningful state oversight and compliance with the federal Mental Health Parity and Addiction Equity Act. This guides health insurers through the necessary analysis to demonstrate compliance with the law, which can then be made available to a state department of insurance to streamline regulatory review.

AMA Education Hub: Opioid and Pain Management: Guidelines, Research and Treatments

Fulfill your state-mandated CME credits while enhancing your knowledge of opioid and non-opioid pain management, safe opioid prescribing and substance use treatment. Learn now. CME 44.25 Total Credits

What does a sufficient pain care formulary look like?

The AMA believes it is essential for formularies to also include a broad range of evidence-based pain care options. This resource is meant to provide an overview for policymakers of the types of treatments practicing physicians use to treat pain but may be subject to formulary exclusion or administrative barriers such as prior authorization or step therapy, or subject to cost-prohibitive co-pays, cost sharing and adverse formulary tiering.

Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids

Given the complex needs of pregnant and postpartum women and their children, and the number of systems they encounter during critically important periods in their lives, ASAM provides policy recommendations on substance use, misuse, and SUDs during and following pregnancy.

The AMA Urges Removing All Barriers to Treatment for Substance Use Disorder

Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System

JAMA Psychiatry Traci C. Green, PhD, MSc; Jennifer Clarke, MD; Lauren Brinkley-Rubinstein, PhD; Brandon D. L. Marshall, PhD; Nicole Alexander-Scott, MD, MPH; Rebecca Boss, MA; Josiah D. Rich, MD, MPH

Public Policy Statement on the Regulation of Office-Based Opioid Treatment

Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy

AMA Journal of Ethics. September 2017, Volume 19, Number 9: 922-930. Sarah E. Wakeman, MD

Preparation and Administration of Extended-Release Naltrexone

A Primer on Antagonist-Based Treatment of Opioid Use Disorders in the Office Setting

AMA Opioid Task Force

The AMA Opioid Task Force urges physicians and other health care professions to continue taking action to help reverse the nation’s opioid epidemic—and the Task Force also calls on policymakers to take specific steps to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.

Learn More

Be part of the solution.

Join the AMA today and help us lead the effort
to reverse the nation’s opioid epidemic.